Dapoxetine hydrochloride versus paroxetine for the treatment of primary premature ejaculation.
- Author:
Ting-You ZHOU
1
;
Zheng LI
1
;
Ying KANG
1
;
De-Ling GONG
1
;
Qi ZHOU
1
;
Tian-Su LI
1
Author Information
1. Center of Urology and Andrology, People's Hospital of Qianxinan Prefecture, Xingyi, Guizhou 562400, China.
- Publication Type:English Abstract
- Keywords:
premature ejaculation;
paroxetine;
dapoxetine;
intravaginal ejaculation latency time;
Premature Ejaculation Profile
- MeSH:
Humans;
Benzylamines/therapeutic use*;
Male;
Premature Ejaculation/drug therapy*;
Naphthalenes/therapeutic use*;
Paroxetine/therapeutic use*;
Adult;
Treatment Outcome;
Middle Aged;
Young Adult;
Selective Serotonin Reuptake Inhibitors/therapeutic use*
- From:
National Journal of Andrology
2025;31(5):432-437
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical effect and adverse reactions of dapoxetine hydrochloride versus paroxetine in the treatment of primary premature ejaculation by cross-comparison.
METHODS:Based on the clinic-visit time, we equally randomized 148 patients with primary premature ejaculation into groups A and B for a cross-comparison test, the former treated with paroxetine at 20 mg once nightly and the latter with dapoxetine hydrochloride at 30 mg on demand, both for 6 successive weeks, during which we observed the therapeutic effects and adverse reactions. Following 4 weeks of drug discontinuance, we administered dapoxetine hydrochloride at 30 mg on demand for group A and paroxetine at 20 mg once nightly for group B, both for another 6 successive weeks, followed by observation and comparison of the therapeutic effects and adverse reactions.
RESULTS:There were no statistically significant differences in the initial characteristics of the two groups of patients (P > 0.05). Compared with the baseline, the mean intra-vaginal ejaculation latency time (IELT) was dramatically improved after treatment in both groups A (4.43 min) and B (7.12 min), increased by 3.99% and 6.72%, respectively (P<0.001). The patients treated with paroxetine showed significantly longer IELT than those taking dapoxetine hydrochloride in both groups (P<0.001). Findings of the Premature Ejaculation Profile (PEP) and spouses' conditions indicated significant improvement after treatment in the average scores of the four indicators of PEP, that is, perceived control over ejaculation, ejaculation-related personal distress, satisfaction with sexual intercourse and ejaculation-related interpersonal difficulty, as well as in the overall experience and partner's satisfaction and orgasm frequency. Adverse reactions to medication were found in 20.8% of the cases in group A and 9.7% in group B, but none was serious. Preference survey following drug withdrawal revealed a preference for paroxetine (61.9%) over dapoxetine (26.8%), and that only a few of the patients thought of the two drugs as comparable or both ineffective.
CONCLUSION:In term of overall effectiveness, paroxetine was superior to dapoxetine in the treatment of primary premature ejaculation. And the patients obviously preferred the former to the latter, which might be partly attributed to the higher price of dapoxetine.
